Melitracen Research Articles

Clinical study of mosapride and esomeprazole combined with flupentixol and melitracen tablets in the treatment of refractory gastroesophageal reflux disease

目的 回顾性研究莫沙必利与埃索美拉唑联合氟哌噻吨美利曲辛片治疗难治性胃食管反流病(RGERD)的效果。 方法 选取2016年3月至2017年9月运城市中心医院收治的RGERD患者68例为研究对象，按照治疗方案不同分为观察组(n=34)与对照组(n=34)。对照组予以莫沙必利+埃索美拉唑治疗，观察组予以莫沙必利+埃索美拉唑+氟哌噻吨美利曲辛片治疗，比较两组疗效、治疗前后反流性疾病问卷(RDQ)积分、抑郁自评量表(SDS)评分、焦虑自评量表(SAS)评分、食管测酸指标变化及食管测压指标变化。 结果 治疗后观察组RDQ积分改善情况优于对照组(P 0.05)；两组治疗前后食管测压指标差异无统计学意义(P>0.05)。 结论 采用莫沙必利与埃索美拉唑联合氟哌噻吨美利曲辛片治疗RGERD疗效显著，可缓解患者临床症状，改善其负性情绪，值得临床推广应用。

The clinical trials of Chaihu-Longgu-Muli decoction combined flupentixol and melitracen tablets for the post-stroke depression

Objective To observe the effect of Chaihu-Longgu-Muli decoction combined flupentixol and melitracen tablets for the post-stroke depression (PSD). Methods The random number table method was used to divide the 150 patients with PSD into the observation group and control group, 75 cases in each group. On the basis of conventional treatment of stroke, the control group took oral flupentixol and melitracen tablets, and the treatment group add Chaihu-Longgu-Muli decoction on the basic treatment of control gorup. The treatment of two groups last 1 month. The serum APN concentration was detected before and after treatment. Besides, the HAMD, NIHSS scores, and the clinical curative effect were observed and compared. Results The total effective rate of the observation group was 81.3%, and control group was 58.7%, which the difference between the two groups showed the statistical significance (P<0.05). After treatment, the serum APN (7.8 ± 3.7 mg/L vs. 6.1 ± 3.3 mg/L, t=2.970) level in the observation group was significantly higher than that in the control group (P<0.05). The HADM (16.4 ± 3.6 vs. 19.6 ± 4.9, t=4.558), NIHSS (5.0 ± 1.6 vs. 7.7 ± 2.0, t=9.129) scores in the observation group were significantly lower than those in the control group (P<0.01). Conclusions The Chaihu-Longgu-Muli decoction combined flupentixol and melitracen tablets can reduce the serum APN level of PSD patients, improve patients with depression, alleviate patients' neurologic deficits. Key words: Stroke; Depression; Chaihu-Longgu-Muli decoction; Adiponectin

Effect of lansoprazole combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety

Objective To observe the clinical effect of lansoprazole enteric-coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety. Methods Eighty patients with erosive gastritis complicated with anxiety were selected, and they were randomly divided into control group(n=40) and observation group(n=40) according to the digital table.The control group was treated with lansoprazole enteric-coated tablets.The observation group received lansoprazole enteric-coated tablets combined with flupentixol and melitracen.Hamming anxiety scale(HAMA) and Hamilton depression scale(HAMD) were used to evaluate in the two groups before and after treatment.The changes of HAMA and HAMD scores were compared between the two groups. Results Before treatment, the scores of abdominal pain, bloating, pantothenic acid and belching had no statistically significant differences between the two groups (all P>0.05). After treatment for 4 weeks, the scores of abdominal pain, bloating, pantothenic acid and belching in the observation group were (0.63±0.12)points, (0.43±0.11)points, (0.30±0.11)points and (0.31±0.14)points, respectively, which were lower than those in the control group [(1.42±0.18)points, (1.08±0.15)points, (0.79±0.16)points, (0.98±0.25)points] (t=15.396, 13.285, 16.758, 17.492, all P 0.05). Conclusion Lansoprazole enteric-coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety can relieve anxiety and depression, improve clinical symptoms and treatment effect. Key words: Lansoprazole; Flupentixol melitracen; Gastritis; Anxiety

Efficacy of conventional treatment combined with flupentixol and melitracen in reflux esophagitis

Objective To investigate the clinical efficacy of conventional treatment combined with flupentixol and melitracen in patients with reflux esophagitis (RE). Methods From June 2012 to March 2015, a total of 182 patients were selected as study subjects from newly diagnosed RE patients. The anxiety and depression scores were evaluated according to Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD). And then patients were divided into HAMA and HAMD negative conventional treatment group and combined treatment group, HAMA and HAMD positive conventional treatment group and combined treatment group. Rabeprazole and mosapride were administrated in conventional treatment group. For patients in combined treatment group, on the base of conventional treatment flupentixol and melitracen were added. The treatment course was eight weeks. The degree of anxiety and depression, RE symptoms and mucosal healing under gastroscope were evaluated before and after treatment. Adverse drug reaction was observed. Chi square test or t test was performed for statistical analysis. Results Eight weeks after treatment, the scores of HAMA and HAMD in HAMA and HAMD positive combined treatment group were 7.930±3.832 and 9.630±3.650, which were both lower than those of conventional treatment group (11.660±4.108 and 12.170±4.459), and the differences were statistically significant (t=3.683 and 2.233; both P 0.05). After treatment, the mucosal healing rate of HAMA and HAMD positive combined treatment group was 91.3%(42/46), which was higher than that of conventional treatment group (71.7%, 33/46), and the difference was statistically significant (χ2=5.845, P=0.016). The incidence of adverse events of HAMA and HAMD negative combined treatment group was 4.8%(2/42), and that of HAMA and HAMD positive combined treatment group was 2.2%(1/46). Conclusions The conventional treatment combined with flupentixol and melitracen in RE patients accompanied with anxiety and depression was remarkable and safe. RE patients without obvious anxiety or depression, preventive use of antianxiety and antidepressant medicine can not improve the efficacy. Key words: Antianxiety; Antidepressant; Esophagitis, peptic; Combined treatment

The clinical efficacy of fluoride faction shouted tons melitracen sheet for functional gastrointestinal disorders with abdominal pain symptoms

Objective To study and analyze the effect of fluoride faction shouted tons melitracen sheet (Deanxit) on abdominal pain symptoms of functional gastrointestinal disorders (FGIDs). Methods 82 patients with abdominal pain FGIDs were randomly divided into A group(n=40) and B group(n=42). A group was given conventional treatment, group B was given deanxit treatment on the basis of A group.The treatment efficacy and the total incidence of adverse reactions were analyzed. Results The total effective rate of group B (90.24%) was significantly higher than that in group A (65.85%), the difference was statistically significant (χ2=4.538, P 0.05). Conclusion Deanxit in the treatment of FGIDs can achieve satisfactory therapeutic effect, the drug can significantly alleviate the symptoms, andit is safe and without serious side effects. Key words: Functional gastrointestinal disorders; Fluoride faction shouted tons melitracen; Abdominal pain; Clinical efficacy

Supplemented Ganmai-Dazao decoction for malignant tumor-related depression: comparsion with flupentixol and melitracen tablets

Objective To evaluate the curative effect of supplemented Ganmai-Dazao decoction for malignant tumor correlation with depression. Methods A total of 98 patients with malignant tumor-related depression were divided into a treatment group and a control group according to the random number table. The control group were treated with flupentixol and melitracen tablets (Deanxit) combined with conventional treatment, the treatment group were treated with oral administration of traditional Chinese medicine supplemented Ganmai-Dazao decoction combined with conventional treatment for 8 weeks. The Hamilton Depression Scale (HAMD) was used to evaluate the curative effect. Results The effective rate showed no significant difference between the treatment group and the control group (79.59% vs. 75.51%; χ2=0.059, P=0.809). HAMD scores in both groups were significantly decreased after the treatment than before treatment (12.8 ± 3.4 vs. 29.4 ± 4.7 in the treatment group, 12.3 ± 3.6 vs. 28.7 ± 4.5 in the control group, all P<0.05), there was no significant difference in HAMD scores after the treatment between the treatment group and the control group (t=0.707, P=0.481). Conclusion Curative effect of supplemented Ganmai-Dazao decoction is equal to flupentixol and melitracen tablets in patients with malignant tumor-related depression. Key words: Neoplasms; Depression; Antidepressive agents; Drugs, Chinese herbal; Gan Mai Da Zao Tang

Fluorescence spectroscopy in process analytical technology (PAT): simultaneous quantification of two active pharmaceutical ingredients in a tablet formulation.

Many pharmaceuticals include highly potent active pharmaceutical ingredients (API), which only require a small dosage to obtain the desired therapeutic effect. This leads to a challenge for quantification of the API using process analytical technology, since the standard nondestructive measurement technique, near-infrared spectroscopy, is not able to quantify below 1% (weight/weight (w/w)) API content. In formulations with more than one API, this challenge is further increased. The purpose of this study is to scrutinize the potential of fluorescence spectroscopy for the simultaneous quantification of two APIs: flupentixol (FLU) in low dosage (0.208-0.625% w/w free base) and melitracen (MEL) (4.17-12.5% w/w free base) in a tablet formulation. Despite internal quenching between the ingredients and the two APIs, this paper demonstrates that it is possible to establish calibrations using partial least squares (PLS) regression on unfolded fluorescence landscapes with a root mean square error of prediction and relative error of 0.038% (w/w) and 9.1%, for FLU and 0.344% (w/w) and 4.1% for MEL, respectively.

Effects of anti-somatisation therapy on the quality of life in patients with functional dyspepsia

Objective To explore somatic symptoms of patients with functional dyspepsia (FD) and effects of combined anti somatisation therapy on the quality of life in patients with FD.Methods Two hundred and nineteen patients with FD were enrolled.Patient Health Questionnaire-15 (PHQ-15) and Nepean Dyspepsia Index (NDI) were completed,and the relation between them was analyzed.Lansoprazole,mosapride and flupentixol melitracen (the anti-somatisation medication) were taken for four weeks by 131 FD patients who had poor response to four-week conventional treatment with proton pump inhibitors (PPI) and/or prokinetic medication and who got more than 4 scores in PHQ 15.And then therapeutic effects were observed and the changes of NDI before and after treatment were analyzed.The t test,chi-square test,Spearman's correlation and linear regression were performed for statistical analysis.Results The total PHQ-15 and NDI score of 219 patients with FD were 5.7±3.4 and 42.0± 10.4,and there was positive correlation between them (r=0.493,P＜0.05).Stomach pain,headache,chest pain,dizziness,shortness of breath,fatigue,sleeping disorder,thirst and so on were positively correlated with totalNDIscore (r=0.262,0.230,0.241,0.243,0.352,0.385,0.266,0.281,all P＜0.05).Chest pain,stomach pain,shortness of breath,dizziness and fatigue were the influence factors of NDI (t=2.340,2.488,5.278,2.167,2.443,all P＜0.05).Among 131 patients with FD who received anti somatisation combination therapy,six patients did not complete the therapy because of the side effects,and finally 125 patients were enrolled and analyzed.Before and four weeks after the treatment,the total PHQ-15 scores of 125 patients with FD were 7.3±3.2 and 2.9±2.2,respectively; and the difference was statistically significant (t =12.653,P＜0.01).There were significant differences in the influence of stomach pain,headache,chest pain,dizziness,shortness of breath,fatigue,sleeping disorder and thirst before and after the treatment (not bothered at all,bothered a little,bothered a lot) (x2=39.231,6.796,6.693,15.520,6.698,51.572,44.390 and 16.506,all P＜0.05).The total NDI score before and after the treatment were 44.3 ± 11.7 and 29.2 ± 6.9,and the difference was statistically significant (t=12.503,P＜0.01).Conclusions The quality of life in patients with FD is affected by somatic symptoms such as chest pain,stomach pain,shortness of breath,dizziness,fatigue and so on.For FD patients with poor response to conventional treatment,the quality of life could be improved by the combination of anti-somatisation therapy and the conventional therapy. Key words: Dyspepsia; Somatisation; Quality of life; Treatment

Clinical outcomes of flupenthixol melitracen combined with conventional drugs on refractory asthma with anxiety and/or depression

Objective To investigate the clinical outcomes of flupenthixol melitracen on refractory asthma with anxiety and/or depression. Methods 105 patients with refractory asthma, who were given asthma controlled test (ACT) and comprehensive hospital anxiety and depression scale (HAD)test, were randomly classified into control group and treatment group, the former used recommended classical drugs in the consensus, Salmeterol Xinafoate and Fluticasone Propionate and Montelukast; while the latter used above therapy combining flupentixol melitrace. HAD score, ACT score and pulmonary function were applied to assess therapeutic effect. Results In 105 cases of refractory asthma patients, 75 patients were complicated with anxiety and/or depression, with prevalence of 71.42%. With the alleviation of anxiety and/or depression, the degree of asthma controlled was improved. After treatment, HAD score of the treatment group was lower that of control group((10.67±2.32)scores vs (11.94±3.02)scores, t=2.06, P<0.05), ACT score in treatment group was much higher than that of control group((14.54±3.14)scores vs (11.25±3.06)scores, t=4.59, P<0.01), there were statistical significance in FEV1%pre between two groups((55.29±5.72)vs (43.36±7.13), t=8.02, P<0.01). Conclusion Antidepressant treatment can alleviate anxiety and/or depression, improve the clinical curative effect of refractory asthma and help to improve lung function. Key words: Anxiety; Depression; Refractory asthma; Flupentixol Melitracen

Research of traditional Chinese medicine and umbilical treatment on diarrhea-predominant irritable bowel syndrome with mental disorders

Objective To observe the traditional Chinese medicine （TCM） and umbilical treatment on diarrhea-predominant irritable bowel syndrome（IBS-D）with mental disorders. Methods Thirty-seven cases with IBS-D were randomized into a treatment group（33 cases） and a control group（31 cases）. The treatment group was given Shugan-Jianpi TCM decoction and pepper umbilical dressing. The control group was given Pinaverium Bromide Tablets and Flupentixol and Melitracen tablets. After having been treated for 4 weeks, Hamilton Anxiety Scale（HAMA）, Hamilton Depression Scale（HAMD）, IBS Symptom Severity Scale（IBS-SSS）, IBS quality of life questionnaire （IBS-QOL） were determined. Results After the treatment, HAMD, HAMA, IBS-SSS in the treatment group and the control group all significantly decreased （the treatment group t=14.280, 13.530, 18.847,the control group t=11.514, 9.424, 13.829, P〈0.01）, and IBS-QOL increased markedly（t=-16.848, -11.712, P〈0.01）. Compared with HAMA, IBS-SSS and IBS-QOL in treatment group, the control group showed statistical difference（t=-3.183, -2.549, 3.904, P〈0.01 or 0.05）. The total effective rate of the treatment group was 94%higher than 75%of the control group（χ^2=4.727, P〈0.05）. Conclusion Shugan-Jianpi TCM decoction and pepper umbilical dressing can improve the clinical symptoms and psychological symptoms and improve the quality of life of IBS-D patients. Key words: Traditional Chinese medicine; Umbilical treatment; Irritable bowel syndrome with diarrhea; Mental disorders

Clinical observation of tolterodine combined with flupentixol melitracen in the treatment of patients with overactive bladder

Objective To investigate the clinical efficacy and safety of tolterodine combined with flupentixol melitracen in the treatment of women with overactive bladder (OAB).Methods 84 female patients with OAB were chosen and randomly divided into the observation group and the control group.42 cases in observation group were treated with tolterodine combined with flupentixol melitracen.42 cases in control group were only treated with tolterodine.The clinical efficacy was recorded and compared after treatment for 4 weeks.Results The total effective rate of the observation group was higher than the control group (95.24％ vs 76.19％,x2 =6.291,P ＜ 0.05).The 24h frequency of urination,the average 24h number of incontinence episodes,initial urinate capacity and maximum bladder pressure capacity had statistically significant differences between the two groups (all P ＜ 0.05).Conclusion Tolterodine combined with flupentixol melitracen in the treatment of women with OAB has advantages of short course of treatment,excellent efficacy,and few side effects. Key words: Tolterodine ; Flupentixol melitracen ; Overactive bladder

Study on the efficacy of flupenthixol melitracen combined with domperidone in the treatment of patients with functional dyspepsia accompanied by anxiety and depression

Objective To evaluate the efficacy and adverse effects of flupenthixol meditracen combined with domperidone in the treatment of patients with functional dyspepsia(FD) accompanied by anxiety and depression.Methods The clinical trial was a multi-centre,open,randomized,controlled,prospective study.The patients wiht FD accompanied by anxiety and depression from eight hospitals were divided into control group and experimentd group.The patients of control group were treated with domperidone 10 mg three times per day.On the basis of the treatment of control group,the patients of experimental group were given deanxit one tablet (flupentixol 0.5 mg and melitracen 10 mg) after breakfast and lunch per day.The patients were evaluated by the gastrointestinal symptom rating scale(GSRS),the hospital anxiety and depression scale (HAD),the Hamilton anxiety scale (HAMA) and the Hamilton depression rating scale (HAMD) when enrolled and were followed up at the first,second and fourth week.The adverse effects were recorded.Using rank sum test,chisquare test and t-test to comparison of efficacy between the two groups,respectively.Results A total of 209 patients were enrolled during the trial,including 105 patients in control group and 104 patients in experimental group.Before the treatment,there were no statistical difference between the two groups in gastrointestinal symptoms,the water loading test and the hospital depression scale (all P＞ 0.05).However,the scores of hospitol anxiety scale,HAMA and HAMD in the experimental group were significantly higher than those of control group (t=2.405,3.982,3.374; all P＜0.05).After one week of treatment,the symptoms of both two groups improved.And the longer duration of the treatment,the more obvious of the efficacy.The efficacy of the experimental group was always better than that of the control group.Both of the complete remission rate and significant efficacy rate of the experimental group were higher than those of control group (19.2％,20/104 vs 5.7％,6/105; 37.5％,39/104 vs 11.4％,12/105; Z=4.935,P＜0.01).After four weeks of treatment,the decrease of the scores of HADS,HAMA and HAMD of experimental group was greater than those of control group (HAD:Z=6.779,6.667,HAMA:Z=6.896; HAMD:Z=8.867; all P＜0.01).Besides,51.9 ％ (54/104) patients with FD accompanied by depression became normal,the percentage was higher than that of control group (23.8％,25/105) and the difference was statistically significant (x2 20.460,P＜0.01).During treatment,the common adverse effects were dry mouth and constipation,which were mild and needed no special treatment.Conclusion Flupenthicol melitracen combined with domperidone demonstrateds significant efficacy in the treatment of FD accompanied by anxiety and depression without obvious adverse effects and is worthy of clinical application. Key words: Dyspepsia; Depression; Flupenthixol; Domperidone

Clinical observation on flupentixol and melitracen combined with metoprolol in the treatment of patients with cardiac neurosis

Objective To explore the clinical effect of flupentixol and melitracen combined with metoprolol in the treatment of patients with cardiac neurosis.Methods 57 patients with cardiac neurosis were divided into the control group and treatment group randomly.The control group received therapy of metoprolol and oryzanol ;The treatment group received additional therapy of flupentixol and melitracen based on treatment of the control group.Clinical effect,scores of HAMD and HAMA were observed and compared between the two groups.Results The total efficient rate of the treatment group was 96.67％,and significantly higher than that of the control group (85.19％) (x2 =21.814,P ＜0.05) ;HAMA and HAMD scores decreased significantly in all patients after treatment(all P ＜ 0.05),more significantly in the treatment group than those in the control group(all P ＜ 0.05).Conclusion Flupentixol and melitracen combined with metoprolol in the treatment of patients with cardiac neurosis has good effect,which is worthy of clinical application. Key words: Cardiac neurosis ; Metoprolol ; Flupentixol ; Melitracen

Meta-analysis of the effect of flupentixol and melitracen combined with conventional medicine on irritable bowel syndrome

Objective To evaluate the efficacy difference between flupentixol and melitracen combined with conventional medicine and conventional drug alone in the treatment of irritable bowel syndrome (IBS).Methods Studies on flupentixol and melitracen combined with conventional medicine (pinaverium bromide and trimebutine maleate) and conventional medicine alone in the treatment of IBS were collected and reviewed through searching the Chinese Academic Journals Full-text Database,Chinese VIP Full-text Database and PubMed database.After that,the test for homogeneity and the combined effect test were estimated. Results A total of 12 clinical studies on flupentixol and melitracen combined with conventional medicine for four to twelve weeks in the treatment of IBS were collected six studies indicated the homogeneity test of flupentixol and melitracen combined with pinaverium bromide (x2 =1.90,df=5,P=0.86,I2 =0).For the fixed-effect model,the odds ratio was 7.92 and 95％ CI was between 4.85 and 12.95,which suggested the combined therapy was better.The other six studies indicated the homogeneity test of flupentixol and melitracen combined with trimebutine maleate (x2 =5.60,df=5,P =0.35,I2 =10.6 ％).For the fixed-effect model,the odds ratio was 5.91 and 95％ CI was between 4.06 and 8.61,which suggested the combined therapy was better.After merging the 12 studies it indicated the homogeneity test of flupentixol and melitracen combined with conventional medicine (x2 =8.40,df =11,P =0.68,I2 =0).For the fixed effect model,the odds ratio was 6.63 and 95％ CI was between 4.92 and 8.93.Conclusion The efficacy of flupentixol and melitracen combined with conventional medicine in the treatment of IBS was better than that of conventional medicine alone,however,still more high quality trials are needed for further confirmation. Key words: Flupenthixol; Calcium channel blockers; Trimebutine; Maleates; Irritable bowel syndrome; Meta-analysis

Deanxit in the treatment of patients with functional dyspepsion but without symptoms of anxiety and depression

Objective To explore the efficacy of tritherapy with omeprozole, mosapride and Deanxit ( flupentixol + melitracen ) for patients with functional dyspepsion but without symptoms of anxiety and depression.Methods One hundred and sixteen patients were randomly assigned to receive either omeprozole and mosapride ( 58 patients,control group ) or tritherapy with omeprozole,mosapride,and Deanxit ( 58 patients, study group ).The efficacies were observed in both groups eight weeks after treatment.Results There was a significant difference in total effectiveness rate between the control group and the study group ( 62.1％ vs.87.9％,P＜ 0.05 ).No obvious adverse reactions were found in the two groups.Conclusions Deanxit has a satisfactory efficacy and slight adverse reactions in the treatment of patients with functional dyspepsion but without symptoms of anxiety or depression. Key words: Melitracen and flupentixol; Functional dyspepsia